Article and Video CATEGORIES
Clinical Trial Spotlight: ALCHEMIST for Early-Stage ALK+ and EGFR Lung Cancer Patients
Dr. Nathan Pennell discusses ALCHEMIST, an NCI-sponsored clinical trial looking at whether targeted post-op (adjuvant) therapy for patients with a driver mutation such as EGFR mutation or ALK rearrangement improves survival.
November is Lung Cancer Awareness Month. What are you grateful for?
Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.
[powerpress]
[ratingwidget post_id=0]
Please feel free to offer comments and raise questions in our
discussion forums.
